<-  All posts

Diag-Nose.io receives Green Light from Bellberry to Commence ENBOARD Clinical Study

The News

We are pleased to announce that Bellberry Human Research Ethics Committee (HREC) has granted approval for the ENBOARD clinical study (Evaluation of Nasal Biomarkers for Objective Assessment of Disease Severity in Respiratory Disorders). This milestone allows us to move forward with participant recruitment and data collection for one of the most comprehensive nasal biomarker studies conducted to date.

The ENBOARD study aims to establish correlations between nasal molecular biomarkers and disease severity in patients with chronic respiratory conditions, including asthma, chronic rhinosinusitis, and COPD. Additionally, the study will validate the tolerability and performance of the ABEL nasal microsampler, a non-invasive device designed to collect high-quality nasal fluid samples for biomarker analysis.

With this approval, we are set to launch recruitment at our clinical site, bringing us closer to transforming respiratory disease monitoring through biomarker-driven insights.

Why This Matters

Respiratory diseases remain a significant global health burden, yet existing diagnostic tools rely heavily on subjective measures and invasive procedures. ENBOARD seeks to:

✅ Advance biomarker-driven precision medicine by identifying objective molecular signatures linked to disease severity.
✅ Enhance patient outcomes by supporting early intervention and more effective treatment strategies.
✅ Validate novel sampling technologies like ABEL to improve accessibility and ease of respiratory diagnostics.

With Bellberry’s approval, we can now proceed with rigorous clinical validation, bringing us one step closer to integrating nasal biomarkers into routine clinical practice.

What’s Next?

Next, we will initiate participant recruitment at our clinical site, conduct first-in-human studies using the ABEL microsampler, and begin analyzing biomarker data to establish correlations with disease activity and treatment response. 

These findings will support regulatory and commercial pathways for biomarker-based diagnostics, with preliminary results contributing to scientific publications and further validation efforts.

👉 Follow us on LinkedIn for real-time updates on ENBOARD, insights into our biomarker research, and opportunities to get involved in shaping the future of precision respiratory medicine! 🚀

Learn more about the study on the ClinicalTrials.gov entry

About Diag-Nose.io 

Diag-Nose.io, founded in 2020, is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions.

Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies.

The company’s flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics.

Learn more at Diag-Nose.io

About Bellberry Limited

Established in 2004, Bellberry Limited is a national, private not-for-profit organization dedicated to enhancing the welfare of research participants and improving the quality and efficiency of human research across Australia. Bellberry provides streamlined scientific and ethical review of human research projects through its 12 Human Research Ethics Committees (HRECs), which collectively conduct up to 13 meetings monthly. These committees are certified to review a wide range of studies, including clinical drug trials, social science research, and observational studies. Operating independently, Bellberry ensures that all research involving humans adheres to the highest ethical standards and academic integrity. As a profit-for-purpose company, any surplus funds generated are reinvested into the Australian medical research community, further supporting the advancement of health and medical research nationwide. 

Learn more at Bellberry's official website.

The News

We are pleased to announce that Bellberry Human Research Ethics Committee (HREC) has granted approval for the ENBOARD clinical study (Evaluation of Nasal Biomarkers for Objective Assessment of Disease Severity in Respiratory Disorders). This milestone allows us to move forward with participant recruitment and data collection for one of the most comprehensive nasal biomarker studies conducted to date.

The ENBOARD study aims to establish correlations between nasal molecular biomarkers and disease severity in patients with chronic respiratory conditions, including asthma, chronic rhinosinusitis, and COPD. Additionally, the study will validate the tolerability and performance of the ABEL nasal microsampler, a non-invasive device designed to collect high-quality nasal fluid samples for biomarker analysis.

With this approval, we are set to launch recruitment at our clinical site, bringing us closer to transforming respiratory disease monitoring through biomarker-driven insights.

Why This Matters

Respiratory diseases remain a significant global health burden, yet existing diagnostic tools rely heavily on subjective measures and invasive procedures. ENBOARD seeks to:

✅ Advance biomarker-driven precision medicine by identifying objective molecular signatures linked to disease severity.
✅ Enhance patient outcomes by supporting early intervention and more effective treatment strategies.
✅ Validate novel sampling technologies like ABEL to improve accessibility and ease of respiratory diagnostics.

With Bellberry’s approval, we can now proceed with rigorous clinical validation, bringing us one step closer to integrating nasal biomarkers into routine clinical practice.

What’s Next?

Next, we will initiate participant recruitment at our clinical site, conduct first-in-human studies using the ABEL microsampler, and begin analyzing biomarker data to establish correlations with disease activity and treatment response. 

These findings will support regulatory and commercial pathways for biomarker-based diagnostics, with preliminary results contributing to scientific publications and further validation efforts.

👉 Follow us on LinkedIn for real-time updates on ENBOARD, insights into our biomarker research, and opportunities to get involved in shaping the future of precision respiratory medicine! 🚀

Learn more about the study on the ClinicalTrials.gov entry

About Diag-Nose.io 

Diag-Nose.io, founded in 2020, is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions.

Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies.

The company’s flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics.

Learn more at Diag-Nose.io

About Bellberry Limited

Established in 2004, Bellberry Limited is a national, private not-for-profit organization dedicated to enhancing the welfare of research participants and improving the quality and efficiency of human research across Australia. Bellberry provides streamlined scientific and ethical review of human research projects through its 12 Human Research Ethics Committees (HRECs), which collectively conduct up to 13 meetings monthly. These committees are certified to review a wide range of studies, including clinical drug trials, social science research, and observational studies. Operating independently, Bellberry ensures that all research involving humans adheres to the highest ethical standards and academic integrity. As a profit-for-purpose company, any surplus funds generated are reinvested into the Australian medical research community, further supporting the advancement of health and medical research nationwide. 

Learn more at Bellberry's official website.